dm+d

37733411000001108

New Medicines

TalzennaMetastatic castration-resistant prostate cancer - first-line with enzalutamide

Information

Talzenna
Licence extension / variation
Pfizer
Pfizer

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Poly(ADP-ribose) polymerase (PARP) inhibitor
Prostate cancer is the most common cancer in men and makes up 26% of all male cancer diagnoses in the UK. The age-standardised incidence of prostate cancer in the UK in 2014 was 175 per 100,000 population [1]
Metastatic castration-resistant prostate cancer - first-line with enzalutamide
Oral

Further information

Yes

Evidence based evaluations

TalzennaDDR-deficient metastatic castration-sensitive prostate cancer - first-line with enzalutamide

Information

Talzenna
Licence extension / variation
Pfizer
Pfizer

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Poly(ADP-ribose) polymerase (PARP) inhibitor, taken once daily
Prostate cancer is the most common cancer in men and makes up 26% of all male cancer diagnoses in the UK. The age-standardised incidence of prostate cancer in 2014 was 175 per 100,000 population [1]. Germline deleterious mutations in DDR genes are present in 8–16% of metastatic prostate cancer patients. There is strong emerging evidence that some germline and somatic DDR defects may predict the response to poly-ADP ribose polymerase (PARP) inhibitors and platinum-based chemotherapy [2].
DDR-deficient metastatic castration-sensitive prostate cancer - first-line with enzalutamide
Oral